Max Hospital, Saket pioneers India’s first HDF certification program for Nephrologists

Pete Pharma and FABRX announce strategic partnership

Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US

ProBioGen to spearhead GMP manufacturing at Berlin’s gene & cell therapy hub

ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit

Atom enrolls first patient in global phase 2 trial of ABP-745 for acute gout flares

ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases

Novo Nordisk’s amylin therapy cagrilintide shows significant weight loss in phase 3 trial

Cagrilintide represents a novel approach to obesity management

Zhimeng Biopharma’s investigational drug approved to begin phase 2 epilepsy clinical trial in China

This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis

Alcon India launches Unity VCS/CS for vitreoretinal and cataract surgery

Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye

Gilead Sciences breaks ground on new manufacturing and technical development site in US

New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value

CapVest to acquire majority stake in STADA

Bain Capital and Cinven will each retain a minority stake, reflecting their ongoing confidence in STADA’s future growth

Merck’s oral PCSK9 inhibitor Enlicitide shows promising results in phase 3 CORALreef lipids study

Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol